Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 7/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.42 |
| ▸ | TGM2 | P21980 | 12/20 | 0.41 |
| ▸ | F13A1 | P00488 | 10/20 | 0.41 |
| ▸ | TGM1 | P22735 | 7/20 | 0.41 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.40 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1237793 | 0.84 | PIK3CG (0.39) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3C3 | |
| SCHEMBL1235215 | 0.83 | PIK3CG (0.52) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3C3 | |
| SCHEMBL1235277 | 0.82 | PIK3CG (0.44) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3C3 | |
| SCHEMBL1237314 | 0.81 | PIK3CG (0.47) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3C3 | |
| SCHEMBL1236599 | 0.81 | PIK3CG (0.42) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3C3 | |
| SCHEMBL1236816 | 0.79 | PIK3CG (0.47) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3C3 | |
| SCHEMBL16906771 | 0.76 | TGM2 (0.53) | TGM2F13A1TGM1TGM3 | |
| SCHEMBL1237698 | 0.75 | PIK3CG (0.52) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3C3 | |
| SCHEMBL1237822 | 0.72 | PIK3CG (0.49) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3C3 | |
| SCHEMBL1235131 | 0.72 | PIK3CG (0.43) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399497-B2 | Thiazole derivatives and use thereof | MERCK SERONO SA (CH) | 2013-03-19 | — | — | US | disclosed |
| EP-1885716-B1 | THIAZOLE DERIVATIVES AND USE THEREOF | MERCK SERONO SA (CH) | 2012-11-07 | — | — | EP | disclosed |
| US-20110086843-A1 | Thiazole Derivatives and Use Thereof | MERCK SERONO SA (CH) | 2011-04-14 | — | — | US | disclosed |
| US-7879888-B2 | N-(4-methyl-5-{5-[(prop-2-yn-1-ylamino)sulfonyl]-2-thienyl}-1,3-thiazol-2-yl)acetamide; autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection | MERCK SERONO SA (CH) | 2011-02-01 | — | — | US | disclosed |
| US-20080221180-A1 | Thiazole Derivatives and Use Thereof | LABORATORIES SERONO SA (CH) | 2008-09-11 | — | — | US | disclosed |
| EP-1885716-A1 | THIAZOLE DERIVATIVES AND USE THEREOF | Laboratoires Serono SA (CH) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006125803-A1 | THIAZOLE DERIVATIVES AND USE THEREOF | LABORATOIRES SERONO S.A. (CH) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221180-A1 | Thiazole Derivatives and Use Thereof | PDGFRB, PDGFRA, TEC | PIK3CG 2526/4885PIK3CD 1844/4885PIK3CA 1647/4885 |
| US-20110086843-A1 | Thiazole Derivatives and Use Thereof | PDGFRB, PDGFRA, TEC | PIK3CG 2526/4885PIK3CD 1844/4885PIK3CA 1647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.